Key information

Recruitment dates:

15 June, 2018 to 1 January, 2021
(Trial recruitment open)

Trial website:

Acronym:

ICON 9

Clinical trial locations

Location list

Contact: Dr. Susanna Banerjee
Address:
The Royal Marsden Hospital
London and Sutton
Contact: Dr. Shibani Nicum
Address:
Churchill Hospital
Oxford
Contact: Dr. Gordon Jayson
Address:
Christie Hospital
Manchester
Contact: Dr. Charlie Gourley
Address:
Western General Hospital
Edinburgh
Contact: Dr. Rebecca Herbertson
Address:
Royal Sussex County Hospital
Brighton
Contact: Dr. Jonathan Lederman
Address:
University College London Hospital
London
Contact: Dr. Caroline Chau
Address:
Queen Alexander Hospital
Portsmouth
Contact: Dr. Justin Walters
Address:
Kent and Canterbury Hospital
Canterbury
Contact: Dr. Justin Walters
Address:
Queen Elizabeth the Queen Mother Hospital
Margate
Address:
Cheltenham General Hospital
Address:
Mount Vernon Hospital, Northwood
Middx
Address:
Lister Hospital, Stevenage
Herts
Address:
Hammersmith Hospital, London
Address:
University Hospital Coventry & Warwickshire
Address:
Royal Surrey County Hospital
GU2 7XX
Address:
Guy's Hospital
SE1 9RT

Introduction

This is a trial for women with recurrent ovarian, fallopian tube or primary peritoneal cancer, whose disease has been shrunk by chemotherapy. The study will address whether such patients may benefit from maintenance treatment with two new anti-cancer drugs called olaparib and cediranib.  

About the trial

ICON9 is a randomised study and patients will be randomly allocated to receive one or both of the anti-cancer drugs on completion of their chemotherapy (called maintenance treatment). Patients will be in the study for up to 6 years and will continue taking the study tablets until their study doctor thinks they are no longer helping to control the disease. Study tablets may also be discontinued by the study doctor if patients experience side effects that have a negative impact on their quality of life. 


ICON9 aims to find out if one or both anticancer drugs taken as maintenance treatment can effectively control the regrowth of ovarian cancer following a good response to chemotherapy. Maintenance therapy is the treatment of cancer with medication, typically following an initial round of treatment. Maintenance treatment may include chemotherapy, hormone therapy, or targeted therapy. Maintenance therapy is used to avoid or slow the growth/return of cancer after initial treatment.  

Who can take part?

This trial is for women with ovarian cancer that has responded to platinum based treatment (platinum sensitive). Patients with platinum sensitive disease are defined as those who have been off therapy for greater than 6 months after achieving a response to platinum-based first-line therapy such as carboplatin or cisplatin. The trial is for women with recurrent ovarian, fallopian tube or primary peritoneal cancer, whose disease has been shrunk by chemotherapy.

You will have some routine investigations to assess your response to the chemotherapy you are currently having. These will include blood tests (including CA125, kidney and thyroid function), a urine test and a CT or MRI scan of your abdomen and pelvis. You may also have a chest x-ray or a CT scan of your chest. These investigations, which are performed as part of your routine care, will be used as part of the screening process to determine if the ICON9 study is suitable for you. 

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.